Alternative to Dangerous Antipsychotics: FDA Approves Auvelity for Agitation in Dementia
The FDA has approved Auvelity for the treatment of agitation symptoms in patients with Alzheimer's disease. Unlike existing therapies, this is the first non-antipsychotic agent that does not increase the risk of mortality in older adults with dementia.
Alternative to Dangerous Antipsychotics: What Auvelity's Approval Means for Dementia Patients and Their Families
Introduction
On April 30, 2026, the FDA approved Auvelity (a combination of dextromethorphan and bupropion) for the treatment of agitation in adult patients with dementia due to Alzheimer's disease. At first glance, this is merely an expansion of indications for an already known antidepressant. But behind this decision lies a paradigm shift in the treatment of one of the most debilitating symptoms of dementia. For the first time, physicians have a non-antipsychotic agent with a fundamentally different mechanism of action that does not increase the risk of death in elderly patients. Given that agitation affects 50% to 76% of patients with Alzheimer's disease, this decision has the potential to change the quality of life for millions of families.
Event Details and Timeline
The path to this indication for Auvelity took more than five years. The FDA granted the drug Breakthrough Therapy designation for the treatment of agitation in Alzheimer's disease on June 26, 2020. The application was accepted for priority review on December 31, 2025, and the decision was made exactly on the PDUFA date—April 30, 2026.
The registration dossier was based on four clinical studies, the key ones being two randomized, placebo-controlled Phase III trials—ADVANCE-1 and ACCORD-2.
ADVANCE-1 was a five-week double-blind study in which patients received either Auvelity, placebo, or bupropion monotherapy (the latter group was prematurely closed due to futility). The drug met its primary endpoint: the mean reduction on the Cohen-Mansfield Agitation Inventory (CMAI) at week five was 15.4 points versus 11.5 points in the placebo group (P=0.010).
ACCORD-2 had a different design—a randomized withdrawal after an open-label treatment phase. Here, the results were particularly compelling: the relapse rate of agitation in the Auvelity group was only 8.4% versus 28.6% on placebo (P=0.001), and the hazard ratio for time to relapse was 0.275 (P=0.001). As noted by geriatric psychiatry expert George Grossberg, "Auvelity is the only FDA-approved drug that has shown a statistically significant increase in time to relapse of agitation symptoms compared to placebo in a long-term study."
It is important to mention that the ADVANCE-2 study did not meet its primary endpoint on the CMAI (a reduction of 13.8 points versus 12.6 on placebo), although numerical improvements were observed on most measures. Nevertheless, the totality of data from the four studies convinced the regulator of efficacy.
Impact and Significance
The significance of this approval unfolds in three dimensions: clinical, pharmacoeconomic, and social.
Clinical breakthrough lies in the mechanism of action and safety profile. Until now, the only FDA-approved drug for the treatment of agitation in dementia was Rexulti (brexpiprazole) from Otsuka/Lundbeck, which received the indication in 2023. It is an atypical antipsychotic—a class of drugs that the FDA has for decades accompanied with a black box warning about an increased risk of death in elderly patients with dementia. Consequently, antipsychotics are used as a last resort—when there is a threat to the safety of the patient or others.
Auvelity works differently: it blocks NMDA receptors and activates sigma-1 receptors, modulating glutamate and dopamine systems without the direct effect on dopamine D2 receptors characteristic of antipsychotics. The main clinical advantage is a "clean label": Auvelity's prescribing information does not include a boxed warning about increased mortality in elderly patients with dementia. According to long-term follow-up data from 456 patients (up to 12 months), the drug was well tolerated; the only side effect with a frequency ≥5% was headache, and no deaths were reported.
Economic potential is significant. Analysts estimate the target market for agitation in Alzheimer's disease at over $1 billion, with some estimates reaching $1.6 billion in the US alone. In 2025, Auvelity sales for its primary indication (major depressive disorder) already exceeded $500 million, and in the first quarter of 2026, they reached $153.2 million—59% higher than the previous year. The company expanded its sales force to 630 representatives and plans a full commercial launch for the new indication in June 2026.
Social significance cannot be overstated. Agitation is one of the main reasons for premature placement of patients in nursing homes and hospitalization. It is also a leading factor in depression and burnout among caregivers. As FDA Commissioner Marty Makary noted, "Today's decision gives patients and their families access to an additional important treatment for the complications of this devastating disease."
Reactions from Key Players
Axsome Therapeutics' stock reacted sharply to the approval: on April 30, 2026, shares jumped 12.9%, closing at $207.75. Over the month, the increase was more than 20%.
Financial analysts assessed the drug's prospects very positively. Leonid Timashev of RBC Capital Markets called the label "clean" and noted that the safety profile is "best in class for this patient population." His team sees a market opportunity for Auvelity of around $1.6 billion annually. Joseph Thome of TD Securities emphasized that surveyed experts (KOLs) consider the "clean label" a significant improvement over Rexulti and other atypical antipsychotics used off-label. The analyst predicts that Auvelity will quickly capture market share and could become the therapy of choice. According to his models, peak US sales at a 3% market penetration would be $1 billion, but the total addressable market approaches $15 billion.
However, Axsome's first-quarter 2026 earnings report showed a loss of $1.26 per share on revenue of $191.2 million, which fell short of analyst expectations. This reflects high marketing and expansion costs associated with the launch preparation. The company reported having $305.1 million in cash, which management says is sufficient to achieve positive cash flow.
The medical community received the news with enthusiasm. Jeffrey Cummings, Professor of Brain Science at UNLV School of Medicine, characterized the drug as addressing a critical unmet need. Dr. Richard Isaacson of the Institute for Neurodegenerative Diseases in Florida summarized decades of therapeutic vacuum: "We've needed a drug like this for decades, because agitation in Alzheimer's disease is one of the most challenging and distressing symptoms we face."
Forecast and Conclusions
The approval of Auvelity sets several important trends for geriatric psychiatry and the pharmaceutical market.
First trend—decriminalization of agitation therapy. Years of using antipsychotics with their fatal risks have created a persistent wariness among physicians and families. The emergence of a drug with an acceptable safety profile changes the threshold for deciding on pharmacotherapy. Physicians who previously delayed medication until extreme behavioral disturbances now have the opportunity to intervene earlier.
Second trend—market reshaping. With a target addressable market approaching $15 billion and penetration currently estimated in single digits, the growth potential is enormous. Given the absence of a boxed warning about mortality, Auvelity is in a winning competitive position not only against Rexulti but also against numerous off-label antipsychotics.
Third trend—diversification of Axsome's portfolio. The company is not resting on its laurels. In April 2026, Axsome acquired global rights to balopodekt (now AXS-20) from Takeda Pharmaceuticals and plans to start Phase III trials for schizophrenia and Tourette syndrome this year. This is a strategy to transform from a one-product company into a multi-specialty player in the neuropsychiatric market.
However, unresolved questions remain. The drug has its own boxed warning about the risk of suicidal thoughts in adolescents and young adults—although the target population of elderly dementia patients does not overlap with this risk group, the warning may create some concern among relatives. Also, drug interactions must be considered, especially the inhibition of CYP2D6 by the bupropion component, which is critical for elderly patients with multiple comorbidities and polypharmacy.
In the end: On April 30, 2026, the FDA did not simply approve another drug. The regulator opened the door to a new class of therapy for behavioral symptoms of dementia. Seven million Americans with Alzheimer's disease and their families have gained what they lacked for decades—the ability to treat one of the most devastating symptoms of the disease without the agonizing choice between safety and efficacy. Commercial success will depend on the speed of adoption by the medical community, but the clinical need and competitive advantages of a "clean label" suggest that Auvelity may well become the standard of care for agitation in dementia in the coming years.
— Editorial Team
